financetom
Business
financetom
/
Business
/
Roku Stock Is Rising After-Hours Tuesday: Here's Why
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Roku Stock Is Rising After-Hours Tuesday: Here's Why
Jan 21, 2025 2:51 PM

Roku Inc ( ROKU ) shares are trading higher in Tuesday’s after-hours session after Netflix Inc ( NFLX ) reported better-than-expected financial results for the fourth quarter.

What Happened With Netflix: Netflix ( NFLX ) reported fourth-quarter revenue of $10.25 billion, beating analysts estimates of $10.11 billion. The streaming giant reported quarterly earnings of $4.27 per share, beating analyst estimates of $4.19 per share.

Shares appear to be soaring in response to the company’s strong subscriber growth. Netflix ( NFLX ) said it added 18.91 million paid subscribers in the quarter, bringing its total subscriber count up to 301.63 million.

Netflix ( NFLX ) noted that its advertising plan continues to be quite popular, generating over 55% of sign-ups in the quarter. The company’s ads plan grew nearly 30% on a quarter-over-quarter basis.

“We're on track to reach sufficient scale for ads members in all of our ads countries in 2025. A top priority in 2025 is to improve our offering for advertisers so that we can substantially grow our advertising revenue,” the company said.

NFLX Earnings: Netflix ( NFLX ) Q4 Earnings: Record Subscribers, NFL, ‘Squid Game’ Push Past ‘Highest Expectations’

Why It Matters For ROKU: Roku ( ROKU ) is well-positioned to benefit from strong advertising trends from Netflix ( NFLX ) and other streaming companies.

Roku ( ROKU ) creates revenue opportunities with streaming companies through partnerships and advertising. The company operates an advertising distribution platform, allowing it to capitalize on the growth of streaming. Netflix ( NFLX ) was reportedly considering a takeover of Roku ( ROKU ) a couple of years ago, but a deal never materialized.

Roku ( ROKU ) is due to report its fourth-quarter financial results in early February, although a date has not yet been confirmed by the company. Analysts expect Roku ( ROKU ) to report a loss of 41 cents per share and revenue of $1.15 billion, according to estimates from Benzinga Pro.

ROKU Price Action: Roku ( ROKU ) shares were up 3.71% in after-hours, trading at $82.70 at the time of publication Tuesday, according to Benzinga Pro.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Ronald M Shaich, Director, on June 05, 2024, sold 2,550,290 shares in Cava Group ( CAVA ) for $222,512,803. Following the Form 4 filing with the SEC, Shaich has control over a total of 7,149,899 shares of the company, with 5,000 shares held directly and 7,144,899 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024027251/xslF345X03/wk-form4_1717790405.xml Price: 85.00,...
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Jun 7, 2024
04:06 PM EDT, 06/07/2024 (MT Newswires) -- Robert I Blum, Director, President & CEO, on June 04, 2024, sold 22,500 shares in Cytokinetics ( CYTK ) for $1,099,125. Following the Form 4 filing with the SEC, Blum has control over a total of 443,311 shares of the company, with 439,145 shares held directly and 4,166 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224018143/xslF345X03/form4.xml...
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Percy H. Carter, Chief Scientific Officer, on June 05, 2024, sold 4,000 shares in Blueprint Medicines ( BPMC ) for $420,520. Following the Form 4 filing with the SEC, Carter has control over a total of 41,895 shares of the company, with 41,895 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1597264/000141588924015943/xslF345X03/form4-06072024_040602.xml ...
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Christopher Gibson, Director, Chief Executive Officer, on June 05, 2024, sold 100,000 shares in Recursion Pharmaceuticals ( RXRX ) for $871,000. Following the Form 4 filing with the SEC, Gibson has control over a total of 708,738 shares of the company, with 708,738 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000077/xslF345X03/wk-form4_1717790504.xml Price: 8.60, Change: +0.09,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved